Table 2.

Baseline demographic and disease characteristics of patients receiving adalimumab+methotrexate in the ARMADA study

Mean (SD)*	ARMADA (N=67)
	Disease duration		Prior DMARD treatment
	≤5 years n=51	>5–10 years n=16	MTX+0–1 n=41	MTX+2 n=13	MTX+>2 n=13
Age, years	55.2 (10.4)	61.3 (13.6)	55.5 (10.0)	61.4 (14.6)	55.6 (12.0)
Sex, female, n (%)	38 (74.5)	12 (75.0)	32 (78.0)	10 (76.9)	8 (61.5)
RA duration, years	3.6 (1.2)	6.0 (0.0)	3.9 (1.4)	4.2 (1.7)	4.9 (1.2)
Prior DMARD treatments†	1.3 (1.2)	2.1 (1.5)	0.6 (0.5)	2.0 (0.0)	3.6 (1.0)
DAS28(CRP)	5.7 (0.8)	5.5 (0.9)	5.8 (0.7)	5.4 (0.9)	5.5 (0.8)
SDAI	40.1 (10.6)	37.4 (11.2)	41.5 (10.8)	36.8 (10.4)	35.7 (10.1)
HAQ-DI	1.5 (0.6)	1.6 (0.7)	1.5 (0.5)	1.3 (0.7)	2.0 (0.4)

*Values are means (SD) unless specified otherwise.

†Including methotrexate.

DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index.